Current Practices in B7-H3 Testing

Joshua K. Sabari, MD, discusses whether individual B7-H3 analysis is available at his institution, noting that, if it is, he obtains IHC for both PD-L1 and B7-H3 expression levels in all patients with SCLC. If B7-H3 testing becomes available, he would consider adding it to the biomarker assay, particularly at the time of diagnosis or recurrence.

EP: 1.Clinical Impressions and Therapy Goals

EP: 2.Considerations for Extended Chemoimmunotherapy

EP: 3.Prophylactic Cranial Irradiation Considerations

EP: 4.Mechanism of Action of BiTE Immunotherapy

EP: 5.Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes

EP: 6.Significance of Durable Responses in DeLLphi-301 Trial

EP: 7.Expectations for PFS and OS in Relapsed/Refractory SCLC

EP: 8.Future Potential in Combination Therapies

EP: 9.Dual Maintenance With BiTE and PD-L1 Inhibitors

EP: 10.B7-H3 Mechanism and Therapeutic Potential

Now Viewing

EP: 11.Current Practices in B7-H3 Testing

Video content above is prompted by the following:

• Is individual B7-H3 analysis currently available at your institution ?
  If so, do you obtain IHC for both PD-L1 and B7-H3 expression levels in all your patients with SCLC?
  If not, when IHC and/or PC does become available for B7-H3 testing, would you consider adding it to your biomarker assay?
  o At which stage of disease

Recent Videos